{"product_id":"cagrisema","title":"CagriSema","description":"\u003ch2\u003e\u003cstrong\u003eCAGRISEMA GLP-1 \u0026amp; METABOLIC\/WEIGHT\nLOSS PEPTIDES\u003c\/strong\u003e\u003c\/h2\u003e\n\n\u003cp\u003eCagriSema is a highly anticipated, next-generation investigational weight-loss therapy that\ncombines two powerful mechanisms of action into a single, once-weekly injection. Developed by\nNovo Nordisk, it co-formulates the well-established GLP-1 receptor agonist semaglutide with\ncagrilintide, a novel, long-acting amylin analogue. This dual-hormone approach is designed to\nproduce profound, synergistic effects on appetite regulation, gastric emptying, and metabolic\noptimization, targeting weight loss outcomes that push the boundaries of pharmacological\nintervention.\u003c\/p\u003e","brand":"PeptideValidation.com","offers":[{"title":"Default Title","offer_id":46458100875461,"sku":null,"price":0.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0787\/1515\/8725\/files\/CagriSema.png?v=1782826171","url":"https:\/\/peptidevalidation.com\/products\/cagrisema","provider":"PeptideValidation.com","version":"1.0","type":"link"}